• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
KNTE

KNTE

Kinnate Biopharma Inc.

NASDAQHealthcareBiotechnologyUS

USD2.65

-0.01 (-0.38%)

Company Profile

CEO

Nima Farzan

IPO Date

2020-12-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.65

Prev. Close

$2.66

Day Low

$2.64

Day High

$2.67

52W Low

$1.04

52W High

$7.18

Market Cap

$0.12B

Volume

2.12M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

29.8%

Avg Negative

1.1%

Avg Neutral

69.0%

News Feed

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

GlobeNewsWire·7/7/2021·↑ positive

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

GlobeNewsWire·6/4/2021·↑ positive

Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewsWire·5/25/2021·↑ positive

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

GlobeNewsWire·5/13/2021·↑ positive

KNTE Stock Price Increased 7.37%: Why It Happened

Pulse2·3/30/2021·↑ positive

Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results

GlobeNewsWire·3/29/2021·↑ positive

Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index

GlobeNewsWire·3/19/2021·↑ positive

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

GlobeNewsWire·2/11/2021·↑ positive

Why SVB Leerink Is Bullish On Kinnate Biopharma

Benzinga·12/28/2020·↑ positive

Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·12/7/2020·↑ positive